DE69941154D1 - Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen - Google Patents
Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven KarzinomenInfo
- Publication number
- DE69941154D1 DE69941154D1 DE69941154T DE69941154T DE69941154D1 DE 69941154 D1 DE69941154 D1 DE 69941154D1 DE 69941154 T DE69941154 T DE 69941154T DE 69941154 T DE69941154 T DE 69941154T DE 69941154 D1 DE69941154 D1 DE 69941154D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- neu positive
- hydroxamate compounds
- positive carcinomas
- carcinomas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/192,206 US6541214B1 (en) | 1998-11-13 | 1998-11-13 | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
PCT/US1999/027010 WO2000029609A1 (en) | 1998-11-13 | 1999-11-13 | N-terminally truncated her-2/neu protein as a cancer prognostic indicator |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69941154D1 true DE69941154D1 (de) | 2009-09-03 |
Family
ID=22708689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69941154T Expired - Lifetime DE69941154D1 (de) | 1998-11-13 | 1999-11-13 | Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen |
Country Status (7)
Country | Link |
---|---|
US (2) | US6541214B1 (de) |
EP (3) | EP1131461B1 (de) |
JP (1) | JP2002530629A (de) |
AU (1) | AU777803B2 (de) |
CA (1) | CA2350834C (de) |
DE (1) | DE69941154D1 (de) |
WO (1) | WO2000029609A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
US7625859B1 (en) * | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
ES2537514T3 (es) * | 2003-04-04 | 2015-06-09 | Incyte Corporation | Composiciones, métodos y kits relacionados con la escisión de HER-2 |
CA2525969A1 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
EP1651095A4 (de) * | 2003-08-05 | 2008-10-08 | Euro Celtique Sa | ErbB REZEPTOR VERFAHREN UND SETS ZUR BERWACHUNG VON CHEMOTHERAPIE-RESISTENZ |
EP1745073A2 (de) * | 2004-05-14 | 2007-01-24 | Receptor Biologix, Inc. | Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung |
EP1807106A2 (de) * | 2004-10-05 | 2007-07-18 | Oregon Health and Science University | Zusammensetzungen und verfahren zur behandlung von erkrankungen |
CA2595395A1 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
ES2526211T3 (es) | 2007-07-13 | 2015-01-08 | Nestec S.A. | Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos |
CA2711843C (en) * | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
WO2009097425A2 (en) * | 2008-01-29 | 2009-08-06 | Spring Bioscience Corporation | Method for detecting truncated molecules |
NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
BRPI0906309A2 (pt) | 2008-04-02 | 2020-05-26 | Macrogenics, Inc | Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica |
US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
SG177252A1 (en) | 2008-12-01 | 2012-03-29 | Lab Corp America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
KR20110120890A (ko) * | 2009-01-15 | 2011-11-04 | 래버러토리 코포레이션 오브 아메리카 홀딩스 | Her-2 발현의 측정에 의한 환자 반응의 결정 방법 |
CN102460152B (zh) | 2009-01-15 | 2014-11-26 | 美国控股实验室公司 | 通过测量Her-3确定患者反应的方法 |
NZ616755A (en) * | 2009-05-14 | 2015-05-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
US20100332417A1 (en) * | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
EP3144394B1 (de) | 2010-12-08 | 2019-02-06 | Expression Pathology, Inc. | Srm/mrm-test für trunkiertes her2 |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
WO2012159115A1 (en) * | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
WO2017100663A1 (en) | 2015-12-09 | 2017-06-15 | Expression Pathology, Inc. | Improved methods for treating her2-positive breast cancer |
RU2695787C1 (ru) * | 2018-11-07 | 2019-07-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Применение соединения 2-[3-(2-хлорэтил)-3-нитрозоуреидо]-1,3-пропандиол для лечения her2-положительных опухолей в эксперименте |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA71447A (en) | 1900-06-02 | 1901-05-21 | Thomas Morrison | Rolling plangel sections |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のneu関連タンパク質の検出及び定量 |
US5464751A (en) | 1990-04-06 | 1995-11-07 | Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0639982A1 (de) * | 1992-05-01 | 1995-03-01 | British Biotech Pharmaceuticals Limited | Verwendung von mmp hemmer |
EP0642353A1 (de) * | 1992-05-14 | 1995-03-15 | Oncologix, Inc. | Behandlung des vaskularen permeabilitätssyndroms und der kollagenase induzierten krankheit durch administrieren von inhibitoren der matrix-metalloproteinase(20.01.94) |
US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5594106A (en) | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
US5837523A (en) | 1994-05-05 | 1998-11-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US7125969B1 (en) | 1996-11-27 | 2006-10-24 | The Regents Of The University Of California | ETS-related gene overexpressed in human breast and epithelial cancers |
CA2323632A1 (en) * | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Hla-binding peptides and their uses |
US6541214B1 (en) | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
US7396810B1 (en) | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
WO2002090991A2 (en) | 2001-05-03 | 2002-11-14 | Oxford Glycosciences (Uk) Ltd | Proteins and genes for diagnosis and treatment of erbb2-related cancer |
-
1998
- 1998-11-13 US US09/192,206 patent/US6541214B1/en not_active Expired - Fee Related
-
1999
- 1999-11-13 AU AU16246/00A patent/AU777803B2/en not_active Ceased
- 1999-11-13 EP EP99958981A patent/EP1131461B1/de not_active Expired - Lifetime
- 1999-11-13 EP EP10012117A patent/EP2299272A3/de not_active Withdrawn
- 1999-11-13 JP JP2000582590A patent/JP2002530629A/ja active Pending
- 1999-11-13 CA CA002350834A patent/CA2350834C/en not_active Expired - Fee Related
- 1999-11-13 DE DE69941154T patent/DE69941154D1/de not_active Expired - Lifetime
- 1999-11-13 EP EP09166038A patent/EP2147978A3/de not_active Withdrawn
- 1999-11-13 WO PCT/US1999/027010 patent/WO2000029609A1/en active IP Right Grant
-
2002
- 2002-08-26 US US10/228,145 patent/US8093216B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2350834C (en) | 2008-10-07 |
EP1131461A1 (de) | 2001-09-12 |
JP2002530629A (ja) | 2002-09-17 |
EP2299272A2 (de) | 2011-03-23 |
US6541214B1 (en) | 2003-04-01 |
EP1131461B1 (de) | 2009-07-22 |
CA2350834A1 (en) | 2000-05-25 |
US8093216B2 (en) | 2012-01-10 |
EP2147978A2 (de) | 2010-01-27 |
EP2299272A3 (de) | 2011-08-03 |
WO2000029609A1 (en) | 2000-05-25 |
US20030059863A1 (en) | 2003-03-27 |
AU1624600A (en) | 2000-06-05 |
AU777803B2 (en) | 2004-10-28 |
EP2147978A3 (de) | 2010-07-14 |
EP1131461A4 (de) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69941154D1 (de) | Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen | |
DE50009504D1 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
DE69924750D1 (de) | Gerät zur thermischen behandlung von gewebe | |
DE69922914D1 (de) | Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux | |
DE59608738D1 (de) | Verwendung von epinastin für die behandlung von schmerzen | |
DE69528109D1 (de) | Thieno -1,5- benzodiazepin zur Behandlung gastrointestinaler Beschwerden | |
NO20005864D0 (no) | Quinasoler til behandling av hjernesvulst | |
DE69827424D1 (de) | Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe | |
DE69925306D1 (de) | Behandlung von kohlenwasserstoffgas | |
ATA76995A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen | |
DE69936890D1 (de) | Vorrichtung zur Behandlung von Ischämie | |
DE69925865D1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
DE69526935D1 (de) | Verwendung von mycobacterium zur tumorbehandlung | |
DE69719815D1 (de) | Aminoacyl sulfamiden zur behandlung hyperproliferativer störungen | |
DE69943089D1 (de) | Methode zur behandlung von staphylokokkeninfektionen | |
ATE221763T1 (de) | Die verwendung von glyceryltriacetat zur behandlung von onychomykosen | |
ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
DE69939723D1 (de) | Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie | |
ATE226071T1 (de) | Antikonvulsive derivate zur behandlung von neuropathischem schmerz | |
DE69931487D1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
DE60026644D1 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
DE69729735D1 (de) | Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen | |
DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
DE59704933D1 (de) | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |